Search

Fatima Aysha Hussain (Massachusetts Institute of Technology, Massachusetts) and colleagues published a new paper in Science showing rapid evolutionary turnover of mobile genetic elements drives bacterial resistance to phages.

Lore Van Espen (Katholieke Universiteit Leuven, Belgium) and colleagues published a new paper in mSystems showing a previously undescribed highly prevalent phage identified in a Danish enteric virome catalog

Rashedul Islama (Guelph Research and Development Centre, Canada) and colleagues published in Critical Reviews in Food Science and Nutrition a systematic review from basics to omics on bacteriophage applications in poultry production and pro

Ying Liu (Institut Pasteur) and colleagues published a new paper in PLOS Biology on diversity, taxonomy, and evolution of archaeal viruses of the class Caudoviricetes.

Many of us are excited for the upcoming Viruses of Microbes (VoM) 2022, the conference finally taking place this summer in Portugal - after being rescheduled from 2020. In collaboration, the International Society for Viruses of Microorganis

The next Phage Phun is Wed, Nov 24 at 9AM Pacific! Phage Phun: informal, self-serve Zoom breakout rooms, where you can hop between topic-based rooms and meet new phage phriends! At Evergreen we had rooms like ‘Catching up with phriends’, ‘P

The Ohio State University (OSU) Centre of Microbiome Science in collaboration with European Virus Bioinformatics Center and Emergent Ecosystems Response to Change (EMERGE) have launched an ECR-focused virome series. Nominate speakers in the

Hany Anany, Antonet Svircev and Eeva Vainio and I (Paul Hyman) are editing a research topic in Frontiers in Microbiology titled “Beyond humans - virus therapy for pathogens of animals and plants” to highlight work with other systems besides

BioNTech SE has acquired PhagoMed GmbH! PhagoMed is a Vienna, Austria-based phage lysin and phage therapy company. The partnership of PhagoMed with BioNTech will further advance the synthetic lysin technology (LysinBuilder).

Maria Loose (Justus-Liebig University Giessen, Germany) and colleagues published a new paper in Antibiotics showing natural bred ε2-phages have improved host range and virulence against uropathogenic Escherichia coli over their ancestor pha

Sean Meaden (University of Exeter, UK) and colleagues published a new paper in Current Biology showing high viral abundance and low diversity are associated with increased CRISPR-Cas prevalence across microbial ecosystems.

Siân Owen (Harvard Medical School, USA) and colleagues published a new paper in Cell Host & Microbe showing prophages encode phage-defense systems with cognate self-immunity.

Carlos Martinez-Soto (University of Guelph, Canada) and colleagues published a new paper in Viruses showing PHIDA: A high throughput turbidimetric data analytic tool to compare host range profiles of bacteriophages isolated using different

Thank you to everyone who participated in our very first #WorldPhageWeek #scicomm challenge! Overall we had just over 70 individual phage researchers participate, and it was great seeing all the phage posts on Twitter! Thank you again to Dr

For PHAVES #24 next week, veterinarian Dr. Whitney Greene & phage researcher Prof. Julianne Grose will give a talk entitled 'Phage Researcher & Veterinarian Perspective: Phage therapy to combat a shell infection in a sea turtle' on November

Conventional homology-based comparative genomic analyses can only do so much in extracting information from databases. We used phages to test our comparative genomics tool (CALANGO) that considers annotation terms besides sequence data. By

Check out the phage community question on Twitter by Dr. Sabrina Green (@MotherOfPhage). "This is a long shot maybe but does anyone have any Pseudomonas #phages that use the type IV pilus as a receptor? This is not for me but a collaborator

Head to YouTube and check out Bacteriophage in Arabic, a channel with a series of seminars and explanation videos about phage!

TechnoPhage announces first clinical safety results with their phage cocktail, TP-102, now advancing to phase 2. TP-102 is assessed for its safety and tolerability in individuals with diabetic foot ulcers, and showed no adverse effects in t

Adaptive Phage Therapeutics announced a strategic agreement with the Antibacterial Resistance Leadership Group to support a phase 1b/2 cystic fibrosis (CF) study. The randomized, double-blind, placebo-controlled trial will assess the safety